Cerium oxide nanoparticles trigger neuronal survival in a human Alzheimer disease model by modulating BDNF pathway

Current Nanoscience

Volumn 5, Issue 2, 2009, Pages 167-176

  D'Angelo, Barbara ^a   Santucci, Sandro ^a   Benedetti, Elisabetta ^a   Di Loreto, Silvia ^c   Phani, R A ^b   Falone, Stefano ^a   Amicarelli, Fernanda ^a   Cerù, Maria Paola ^a   Cimini, Annamaria ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b Nano Cat Srl   (Italy)

^c CNR   (Italy)

Author keywords

Antioxidant; Cell viability; Neurodegeneration; Oxidative stress; Signal transduction mediators

Indexed keywords

ALZHEIMER DISEASE; ALZHEIMER'S; ANTI-OXIDANTS; ANTIOXIDANT; ANTIOXIDANT PROPERTIES; BIOMEDICAL PROBLEMS; CELL VIABILITY; CERIUM OXIDE NANOPARTICLE; CROSS-DISCIPLINARY; FREE RADICAL PRODUCTIONS; FREE RADICAL SCAVENGERS; FREE-RADICAL DAMAGE; IN-VITRO; NEURITES; NEURODEGENERATION; NEURODEGENERATIVE; NEURODEGENERATIVE DISEASE; NEURONAL DEATH; NEURONAL MARKERS; NEURONAL SURVIVAL; NEUROPROTECTION; NEW THERAPEUTIC AGENT; PARKINSON'S DISEASE; SIGNAL TRANSDUCTION PATHWAYS; THERAPEUTIC TOOLS;

BACTERIOPHAGES; BIOLOGICAL SYSTEMS; CELL DEATH; CERIUM; CERIUM COMPOUNDS; FREE RADICAL REACTIONS; FREE RADICALS; NANOPARTICLES; OXIDATIVE STRESS; OXIDES;

SIGNAL TRANSDUCTION;

AMYLOID BETA PROTEIN[25-35]; ANTIOXIDANT; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CERIUM OXIDE; NANOPARTICLE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA;

ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; BRAIN NERVE CELL; CELL STRUCTURE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOFLUORESCENCE; IN VITRO STUDY; NEURITE; NEUROBLASTOMA CELL; NEUROPROTECTION; NUCLEOSOME; OXIDATIVE STRESS; PHASE CONTRAST MICROSCOPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; VALIDATION PROCESS; WESTERN BLOTTING;

EID: 70350662912     PISSN: 15734137     EISSN: None     Source Type: Journal    
DOI: 10.2174/157341309788185523     Document Type: Article

References (44)

1. Selkoe, D.J. Alzheimer's disease is a synaptic failure. Science, 2002, 298, 789-791.
2. Selkoe, D.J. Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat. Cell. Biol., 2004, 6, 1054-1061. (Pubitemid 39468006)
3. Walsh, D.M.; Selkoe, D.J. A beta oligomers - a decade of discovery. J. Neurochem., 2007, 101, 1172-1184.
4. Varadarajan, S.; Yatin, S.; Aksenova, M.; Butterfield, D.A. Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. J. Struct. Biol., 2000, 130, 184-208. (Pubitemid 30679821)
5. Hellweg, R.; Jockers-Scherübl, M. Neurotrophic factors in memory disorders. Life Sci., 1994, 55, 2165-2169.
6. Connor, B.; Young, D.; Yan, Q.; Faull, R.L.; Synek, B.; Dragunow, M. Brain-derived neurotrophic factor is reduced in Alzheimer's disease. Brain Res. Mol. Brain Res., 1997, 3, 71-81. (Pubitemid 27453116)
7. Garzon, D.; Yu, G.; Fahnestock, M. A new brain-derived neurotrophic factor transcript and decrease in brain-derived neurotrophic factor transcripts 1, 2 and 3 in Alzheimer's disease parietal cortex. J. Neurochem., 2002, 82, 1058-1064. (Pubitemid 34966618)
8. Holsinger, R.M.; Schnarr, J.; Henry, P.; Castelo, V.T.; Fahnestock, M. Quantitation of BDNF mRNA in human parietal cortex by competitive reverse transcription-polymerase chain reaction: decreased levels in Alzheimer's disease. Brain Res. Mol. Brain Res., 2000, 76, 347-354. (Pubitemid 30179772)
9. Phillips, H.S.; Hains, J.M.; Armanini, M.; Laramee, G.R.; Johnson, S.A.; Winslow, J.W. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron, 1991, 7, 695-702.
10. Ferrer, I.; Marín, C.; Rey, M.J.; Ribalta, T.; Goutan, E.; Blanco, R.; Tolosa, E.; Martí, E. BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies. J. Neuropathol. Exp. Neurol., 1999, 58, 729-739.
11. Hock, C.; Heese, K.; Hulette, C.; Rosenberg, C.; Otten, U. Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch. Neurol., 2000, 57, 846-851. (Pubitemid 30397187)
12. Michalski, B.; Fahnestock, M. Pro-brain-derived neurotrophic factor is decreased in parietal cortex in Alzheimer's disease. Brain Res. Mol. Brain Res., 2003, 17, 148-154. (Pubitemid 36332338)
13. Peng, S.; Wu J.; Mufson, E.J.; Fahnestock, M. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. J. Neurochem., 2005, 93, 1412-1421. (Pubitemid 40853264)
14. Murer, M.G.; Yan, Q.; Raisman-Vozari, R. Brain-derived neurotrophic factor in the control human brain and in Alzheimer's disease and Parkinson's disease. Prog. Neurobiol., 2001, 63, 71-124. (Pubitemid 30752602)
15. Siegel, G.J.; Chauhan N.B. Neurotrophic factors in Alzheimer's and Parkinson's disease brain. Brain Res. Brain Res. Rev., 2000, 33, 99-227.
16. Allen, S.J.; Wilcock G.K.; Dawbarn, D. Profound and selective loss of catalytic TrkB immunoreactivity in Alzheimer's disease. Biochem. Biophys. Res. Commun., 1999, 264, 648-651.
17. Rossner, S.; Ueberham, U.; Schliebs, R.; Perez-Polo, J.R.; Bigl, V. Neurotrophin binding to the p75 neurotrophin receptor is necessary but not sufficient to mediate NGF-effects on APP secretion in PC-12 cells. J. Neural. Transm. Suppl., 1998, 54, 279-285. (Pubitemid 28539364)
18. Ruiz-León, Y.; Pascual, A.J. Regulation of beta-amyloid precursor protein expression by brain-derived neurotrophic factor involves activation of both the Ras and phosphatidylinositide 3-kinase signalling pathways. Neurochemistry, 2004, 88, 1010-1018. (Pubitemid 38199323)
19. Garzon, D.J.; Fahnestock, M.J. Oligomeric amyloid decreases basal levels of brain-derived neurotrophic factor (BDNF) mRNA via specific downregulation of BDNF transcripts IV and V in differentiated human neuroblastoma cells. Neuroscience, 2007, 27, 2628-2635.
20. Tong, L.; Thornton, P.L.; Balazs, R.; Cotman, C.W. Beta -amyloid-(1-42) impairs activity-dependent cAMP-response element-binding protein signaling in neurons at concentrations in which cell survival is not compromised. J. Biol. Chem., 2001, 18, 17301-17306. (Pubitemid 37411539)
21. Tong, L.; Balazs, R.; Thornton, P.L.; Cotman, C.W.; Beta-amyloid peptide at sublethal concentrations downregulates brain-derived neurotrophic factor functions in cultured cortical neurons. J. Neurosci., 2004, 28, 6799-6809.
22. Olivieri, G.; Otten, U.; Meier, F.; Baysang, G.; Dimitriades-Schmutz, B.; Müller-Spahn, F.; Savaskan, E. Beta-amyloid modulates tyrosine kinase B receptor expression in SHSY5Y neuroblastoma cells: influence of the antioxidant melatonin. Neuroscience, 2003, 120, 659-665. (Pubitemid 36928064)
23. Chung, D. Nanoparticles have health benefits too. New Sci., 2003, 179, 2410-2416
24. Hoerndli, F.J.; Pelech, S.; Papassotiropoulos, A.; Götz, J. Abeta treatment and P301L tau expression in an Alzheimer's disease tissue culture model act synergistically to promote aberrant cell cycle re-entry. Eur. J. Neurosci., 2007, 26, 60-72. (Pubitemid 47035431)
25. Varadarajan, S.; Kanski, J.; Aksenova, M. Different mechanisms of oxidative stress and neurotoxicity for Alzheimer's Aβ(1-42) and Aβ(25-35). J. Am. Chem. Soc., 2001, 123, 5625-5631. (Pubitemid 32904694)
26. 2. Appl. Phys. Lett., 2002, 80, 3814-3816.
27. Santos, M.J.; Quintanilla, R.A.; Toro, A.; Grandy, R.; Dinamarca, M.C.; Godoy, J.A.; Inestrosa, NC. Peroxisomal proliferation protects from β-Amyloid neurodegeneration. J. Biol. Chem., 2005, 80, 41057-41068.
28. White, J.A.; Manelli, A.M.; Holmberg, K.H.; Van Eldik, L.J.; Ladu, M.J. Differential effects of oligomeric and fibrillar amyloid-beta 1-42 on astrocyte-mediated inflammation. Neurobiol. Dis., 2005, 18, 459-465.
29. Munõz, F.J.; Inestrosa, N.C. Neurotoxicity of acetylcholinesterase amyloid beta-peptide aggregates is dependent on the type of Abeta peptide and the AChE concentration present in the complexes. FEBS Lett., 1999, 450, 205-209. (Pubitemid 29219515)
30. Naiki, H.; Higuchi, K.; Nakakuki, K, Takeda T. Kinetic analysis of amyloid fibril polymerization in vitro. Lab. Invest., 1991, 65, 104-110.
31. Inestrosa, N.C.; Alvarez, A.; Perez, C.A.; Moreno, R.D.; Vicente, M.; Linker, C.; Casanueva, O.I.; Soto, C.; Garrido, J. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron, 1996, 16, 881-891. (Pubitemid 26124065)
32. Aksenov, M.Y.; Tucker, H.M.; Nair, P.; Aksenova, M.V.; Butterfield, D.A.; Estus, S.; Markesbeiy, W. The expression of key oxidative stress-handling genes in different brain regions in Alzheimer's disease. J. Mol. Neurosci., 1998, 11, 151-164
33. Di Loreto, S.; D'Angelo, B.; D'Amico, M.A.; Benedetti, E.; Cristiano, L.; Cinque, B.; Cifone M. G.; Cerù, M.P.: Festuccia C.; Cimini A. A PPARbeta agonists trigger neuronal differentiation in the human neuroblastoma cell line SH-SY5Y. J. Cell. Physiol., 2007, 211, 837-847.
34. Das, M.; Patil, S.; Bhargava, N.; Kang, J.; Riedel, L.M.; Seal, S.; Hickman, J.J. Auto-catalytic ceria nanoparticles offer neuroprotection to adult rat spinal cord neurons. Biomaterials, 2007, 28, 1918-1925.
35. Schubert, D.; Dargusch, R.; Raitano, J.; Chan, S. Cerium and yttrium oxide nanoparticles are neuroprotective. Biochem. Biophys. Res. Commun., 2006, 342, 86-91.
36. Park, E.; Choi, J.; Park, Y.; Park K. Oxidative stress induced by cerium oxide nanoparticles in cultured BEAS-2B cells. Toxicology, 2008, 245, 90-100.
37. Gruden, M.A.; Davidova, T.B.; Mališauskas, M.; Sewell, R.; Voskresenskaya, N.I.; Wilhelm, K.; Elistratova, E.I.; Sherstnev, V.V.; Morozova-Roche,. L.A. Differential neuroimmune markers to the onset of Alzheimer's disease neurodegeneration and dementia: Autoantibodies to Aβ(25-35) oligomers, S100b and neurotransmitters. J. Neuroimmunol., 2007, 186, 181-192. (Pubitemid 46773048)
38. Kim, S.H.; Won, S.J.; Sohn S.; Kwon, H.J.; Lee, J.Y.; Park, J.H.; Gwag B. J. Brain-derived neurotrophic factor can act as a pronecrotic factor through transcriptional and translational activation of NADPH oxidase. J. Cell Biol., 2002, 159, 821-831
39. Chong, Y.H.; Shin, Y.J.; Lee, E.O.; Kayed, R.; Glabe, C.G.; Tenner, A.J. ERK1/2 activation mediates Abeta oligomer-induced neurotoxicity via caspase-3 activation and tau cleavage in rat organotypic hippocampal slice cultures. J. Biol. Chem., 2006, 281, 20315-20325.
40. Ruffels, J.; Griffin, M.; Dickenson, J.M. Activation of ERK1/2, JNK and PKB by hydrogen peroxide in human SH-SY5Y neuroblastoma cells: role of ERK1/2 in H2O2-induced cell death. Eur. J. Pharmacol., 2004, 483, 163-173.
41. Lin, E.; Cavanaugh, J.E.; Leak, R.K; Perez, R.G.; Zigmond, M.J. Rapid activation of ERK by 6-hydroxydopamine promotes survival of dopaminergic cells. J. Neurosci. Res., 2008, 86, 108-117.
42. Wang, R.M.; Zhang, Q.G.; Zhang, G.Y. Activation of ERK5 is mediated by N-methyl-D-aspartate receptor and L-type voltage-gated calcium channel via Src involving oxidative stress after cerebral ischemia in rat hippocampus. Neurosci. Lett., 2004, 357, 13-16.
43. Garcia, L.; Garcia, F.; Llorens, F.; Un zeta, M.; Itarte, E.; Gómez, N. PP1/PP2A phosphatases inhibitors okadaic acid and calyculin A block ERK5 activation by growth factors and oxidative stress. FEBS Lett., 2002, 523, 90-94.
44. Liu, F.; Grundke-Iqbal, I.; Iqbal, K.; Gong, C.X. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur. J. Neurosci., 2005, 22, 1942-1950.